Login / Signup

Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.

B MuresanCarla M MamoloJ C CappelleriM J PostmaB Heeg
Published in: Applied health economics and health policy (2021)
Our results suggest that compared with dasatinib and nilotinib, bosutinib may represent good value for money for treating 2L CP-CML patients.
Keyphrases
  • chronic myeloid leukemia
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes
  • replacement therapy